29 April 2016

High-quality laboratories established at Touchlight

Touchlight has developed high-quality dbDNA™ production labs at Hampton capable of providing dbDNA™ to future licensees for feasibility studies​.

- ENDS -

About Touchlight

Touchlight is a privately-owned biotechnology company based in London, U.K., focussed on the discovery and development of DNA-based genetic medicines, including DNA vaccines and gene therapies. Touchlight has developed a novel, synthetic DNA vector known as “doggybone” or dbDNA™.

dbDNA™ is a minimal, linear, covalently closed structure, that eliminates bacterial sequences. Touchlight’s revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies.

Touchlight is applying dbDNA across advanced therapeutic modalities, both in-house and with partners. The company also provides contract manufacturing capabilities to produce dbDNA as a critical starting material for advanced therapy production through its manufacturing arm, Touchlight DNA Services.

Issued for and on behalf of Touchlight by Instinctif Partners.

For more information please contact:

Jonny Ohlson, CEO Tim Watson / Agnes Stephens /
Tommy Duncan, CBO Katie Duffell
E: info@touchlight.com E: touchlight@instinctif.com
T: +44 20 8481 9200 T: +44 20 7457 2020